Through a better understanding of the causes of prostatecancer progression, Duke clinicians and researchers hope to develop strategies to individually tailor therapy or prevention based on a man’s unique characteristics. Our genes, lifestyles and environment can affect the way prostatecancer develops and responds to certain treatments. We study DNA and other molecules in cancer cells to tailor prostatecancer treatments. Feb 26, 2026 · Dukeresearchers have been closely involved in the development and approval of treatments for men with advanced prostatecancer, including newer hormonal therapies, immunotherapies, chemotherapies, and radiopharmaceuticals. Sep 12, 2024 · DURHAM, N.C. (WTVD) -- Researchers at DukeCancer Institute are sharing new developments when it comes to prostatecancer therapy. According to the American Cancer Society, there are more... We examined initial longitudinal outcomes of mid-life men with an elevated baseline prostate-specific antigen (PSA) following initiation of a novel screening program within a system-wide network. May 22, 2025 · The ARCHES study is a global research initiative led by the DukeCancer Institute. It involved 1,150 patients across the globe with metastatic, hormone-sensitive prostatecancer. te-specific antigen (PSA) screening provides an opportunity for the early detection of men harboring organ-confined prostatecancer (PCa) in whom cure is possible. Nevertheless, screening remains controversial because PSA elevations are difficult to interpret . We examined initial longitudinal outcomes of mid-life men with an elevated baseline prostate-specific antigen (PSA) following initiation of a novel screening program within a system-wide network. May 22, 2025 · The ARCHES study is a global research initiative led by the DukeCancer Institute. It involved 1,150 patients across the globe with metastatic, hormone-sensitive prostatecancer.